Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219336PMC
http://dx.doi.org/10.18295/squmj.2021.21.02.027DOI Listing

Publication Analysis

Top Keywords

complete response
4
response sorafenib
4
sorafenib locally
4
locally recurrent
4
recurrent unresectable
4
unresectable aggressive
4
aggressive fibromatosis
4
complete
1
sorafenib
1
locally
1

Similar Publications

Purpose: Build machine learning (ML) models able to predict pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients based on conventional and radiomic signatures extracted from baseline [F]FDG PET/CT.

Material And Methods: Primary tumor and the most significant lymph node metastasis were manually segmented in baseline [F]FDG PET/CT of 52 newly diagnosed BC patients. Clinical parameters, NAC and conventional semiquantitative PET parameters were collected.

View Article and Find Full Text PDF

The study sought to assess the clinical utility of complete blood count-derived composite scores, suggesting their potential as markers of inflammation and disease severity in Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) with Kawasaki-like features. This retrospective study analyzed data from 71 KD and 73 MIS-C patients and 70 healthy controls. The KD group showed a higher rate of coronary involvement (26.

View Article and Find Full Text PDF

In the field of Structural Health Monitoring (SHM), complete datasets are fundamental for modal identification analysis and risk prediction. However, data loss due to sensor failures, transmission interruptions, or hardware issues is a common problem. To address this challenge, this study develops a method combining Variational Mode Decomposition (VMD) and Sparrow Search Algorithm (SSA)-optimized Gate Recurrent Unit (GRU) for recovering structural response data.

View Article and Find Full Text PDF

The potential benefits of pyrotinib for patients with trastuzumab-insensitive, HER2-positive early-stage breast cancer remain unclear. This prospective, multicentre, response-adapted study evaluated the efficacy and safety of adding pyrotinib to the neoadjuvant treatment of HER2-positive breast cancer patients with a poor response to initial docetaxel plus carboplatin and trastuzumab (TCbH). Early response was assessed using magnetic resonance imaging (MRI) after two cycles of treatment.

View Article and Find Full Text PDF

Background: Polyclonal autologous T cells that are epigenetically reprogrammed through mTOR inhibition and IFN-α polarization (RAPA-201) represent a novel approach to the adoptive T cell therapy of cancer. Ex vivo inhibition of mTOR results causes a shift towards T central memory (T) whereas ex vivo IFN-α promotes type I cytokines, with each of these functions known to enhance the adoptive T cell therapy of cancer. Rapamycin-resistant T cells polarized for a type II cytokine phenotype were previously evaluated in the allogeneic transplantation context.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!